Results 201 to 210 of about 834,303 (333)
Bridging international borders through global health diplomacy: A comprehensive bibliometric analysis of the state of play and leads for advancing this domain. [PDF]
Mittal GC +4 more
europepmc +1 more source
Network Usage Security Policies for Academic Institutions
S. M. Aqil Burney, Mohammed Khan
openalex +1 more source
Third-Party Access Cybersecurity Threats and Precautions: A Survey of Healthcare Delivery Organizations. [PDF]
Gellert GA +4 more
europepmc +1 more source
Information Security and Privacy: Networking Challenges Policy in the Digital World
O.V. Derevianko
openalex +2 more sources
ABSTRACT This review article critically examines the environmental and health hazards of tannery sludge (TS), a complex by‐product of the leather tanning industry. TS is characterized by a diverse array of contaminants, including heavy metals like chromium, organic pollutants such as polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds ...
Yashar Aryanfar +10 more
wiley +1 more source
Mobile Network Softwarization: Technological Foundations and Impact on Improving Network Energy Efficiency. [PDF]
Lorincz J, Kukuruzović A, Begušić D.
europepmc +1 more source
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih +3 more
wiley +1 more source
Autonomous cyber-physical security middleware for IoT: anomaly detection and adaptive response in hybrid environments. [PDF]
Ortiz-Garcés I +2 more
europepmc +1 more source
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane +33 more
wiley +1 more source

